Ad
related to: kelly fsp science and clinical trialspfizerclinicaltrials.com has been visited by 10K+ users in the past month
Search results
Results from the WOW.Com Content Network
Deborah F. Kelly is an American biomedical engineer who is a professor at Pennsylvania State University. Her research makes use of cryogenic electron microscopy to better understand human development and disease. She was elected President of the Microscopy Society of America in 2022. [1]
Dr. Kelly has been elected to the American Society of Clinical Investigation (Council Member, 2002-2005), Association of American Physicians (Council Member, 2017 - 2023; President, 2022-2023) [10][11], Association of University of Cardiologists, Association of Professors of Cardiology and the International Society for Heart Research (ISHR ...
In the interest of national and global public health, C-Path develops large databases of aggregated clinical trial data that can be used to study disease progression. These data are also used to develop and qualify biomarkers and clinical outcome assessment instruments that are shared with the greater community for use in drug development.
Kelly K. Ferguson is an American public health researcher who is a Senior Investigator in the National Institute of Environmental Health Sciences.She leads the Perinatal and Early Life Epidemiology Group, which studies how maternal exposure to chemicals impacts pregnancy and development.
2002: ICON acquired clinical research provider, BPA. [20] 2003: ICON acquired Medeval, a UK-based Phase I facility, and US consulting firm, Globomax [21] [22] 2004: ICON acquired medical imaging specialist, Beacon Bioscience Inc. [23] 2006: ICON acquired outcomes research and health economics specialist, Ovation Research Group [24]
Kelly earned a Ph.D. in biophysics in 1968 [13] and an M.D. in 1969. [citation needed] While a postdoctoral fellow with Hamilton O. Smith at the Johns Hopkins University School of Medicine during 1969-70, [14] Kelly determined the DNA sequences recognized by type II restriction enzymes, which subsequently became major tools in recombinant DNA research. [15]
Over the past thirty-three years Frazer has researched and discovered insights into the molecular underpinnings of a wide variety of human diseases and complex traits. [3] [4] As a postdoctoral fellow she and Edward Rubin pioneered cross-species DNA sequence comparisons between humans and mice resulting in the discovery of evolutionarily conserved non-coding regulatory sequences in the human ...
PPD was founded by Fred Eshelman, Pharm.D., as a one-person consulting firm in 1985. The following year, he expanded the company's scope to include development services and relocated operations from Maryland to North Carolina.
Ad
related to: kelly fsp science and clinical trialspfizerclinicaltrials.com has been visited by 10K+ users in the past month